期刊文献+
共找到386篇文章
< 1 2 20 >
每页显示 20 50 100
Use of Oral Agents and/or Insulin in the Treatment of Diabetes during Pregnancy: An Examination of Outcomes in Pregestational versus Gestational Diabetics 被引量:1
1
作者 Edwin Henslee Amanda Hatton +4 位作者 Selman I. Welt Jennifer Holmes Lindsay Penrose Samuel Prien Naghma Farooqi 《Open Journal of Obstetrics and Gynecology》 2014年第16期1052-1057,共6页
The management of diabetes in pregnancy varies depending on whether the condition was first diagnosed during pregnancy (gestational diabetes) or was diagnosed before pregnancy (pregestational diabetes). Little has bee... The management of diabetes in pregnancy varies depending on whether the condition was first diagnosed during pregnancy (gestational diabetes) or was diagnosed before pregnancy (pregestational diabetes). Little has been published comparing the relative efficacy of various oral agents for the treatment of gestational diabetes and the reported experience with the insulin pump in pregnancy for pregestational diabetes remains meager. We conducted a retrospective chart review of women managed in a specialized diabetic clinic to compare the results of treatment of gestational diabetes with oral agents, glyburide and acarbose, to those treated with split-mixed insulin and treatment of pregestational diabetes with either the insulin pump or conventional splitmixed insulin. Gestational diabetics treated with split-mixed insulin were hospitalized significantly more often (p < 0.001) than those treated with oral agents only. The incidence of several important pregnancy complications (growth restriction, preterm labor, preeclampsia, oligohydramnios) did not differ between groups. Pregestational diabetics managed with an insulin pump had comparable glycemic control, as measured by hemoglobin A1c, to those managed with split-mixed insulin. Infant birth weights and Apgar scores were similar in each group. There were no perinatal deaths in either group. Acarbose and glyburide showed comparable efficacy in treating gestational diabetics. In addition, our experience adds to the small number of pregnant women with pregestational diabetes who were managed with an insulin pump that have been reported in the literature. 展开更多
关键词 DIABETES PREGNANCY TREATMENT Methods Pump oral agents
下载PDF
Utilization Pattern of Oral Hypoglycemic Agents for Diabetes Mellitus Type 2 Patients Attending Out-Patient Department at a University Hospital in New Delhi
2
作者 Mohammad Shamshir Alam Mohammed Aqil +2 位作者 Syed Akmal Shah Qadry Prem Kapur Krishna K. Pillai 《Pharmacology & Pharmacy》 2014年第7期636-645,共10页
Diabetes mellitus is the chronic disorder emerging as major world health problem which increases the rate of morbidity and mortality. The aim of the present study was to ascertain patterns of prescription of oral hypo... Diabetes mellitus is the chronic disorder emerging as major world health problem which increases the rate of morbidity and mortality. The aim of the present study was to ascertain patterns of prescription of oral hypoglycemic agents to type 2 diabetic patients attending a university hospital, and to assess patient compliance. A prospective, observational and non comparative study was conducted in 200 established diabetes mellitus type 2 patients attending outpatient department at Majeedia Hospital, New Delhi, India. Prescriptions from registered patients were included in the study. Once the consultation by the physician was over, the prescriptions were reviewed and the patients were interviewed. The information was collected in an inhouse designed documentation proforma. In a pool of 200 type 2 diabetics, more than half were female (n=106, 53%). The mean age of the patients were found to be 50.4 ± 11.7 years and mean body mass index, 25.8 ± 4.4 kg/m2. A total of 432 oral hypoglycemic agents were prescribed to the patients. Highly significant number of patients were prescribed combination therapy, (n=143, 71.5%) as compared to monotherapy (n=57, 28.5%), 展开更多
关键词 Diabetes Mellitus TYPE 2 Medicine Usage Evaluation Drug UTILIZATION PRESCRIBING Pattern. oral HYPOGLYCEMIC agent
下载PDF
Drug utilization analysis of oral hypoglycemic agents in our hospital during the period of 2003~2005
3
作者 辛海莉 《药学实践杂志》 CAS 2007年第6期393-395,共3页
关键词 口服降血糖药 药效 规定日剂量 糖尿病 合理用药
下载PDF
Gastrocolic fistula in Crohn’s disease detected by oral agent contrast-enhanced ultrasound: A case report of a novel ultrasound modality 被引量:4
4
作者 Shuang Wu Hua Zhuang +1 位作者 Jie-Ying Zhao Yu-Fang Wang 《World Journal of Gastroenterology》 SCIE CAS 2020年第17期2119-2125,共7页
BACKGROUND Fistulas are common complications of Crohn’s disease(CD).Gastrocolic fistulas(GFs)are rare,occult and potentially life-threatening complications.Few cases of GFs have been reported.Oral agent contrast-enha... BACKGROUND Fistulas are common complications of Crohn’s disease(CD).Gastrocolic fistulas(GFs)are rare,occult and potentially life-threatening complications.Few cases of GFs have been reported.Oral agent contrast-enhanced ultrasound(OA-CEUS)is a novel technique of ultrasound(US)for gut.Contrast agent made by Chinese yam is taken orally to dilate the lumen of the upper gastrointestinal tract.Thus,the impediment of gas inside gastrointestinal tract is removed and a good acoustic window is provided for gastroin-testinal tract scanning.This paper describes a case of GF secondary to CD detected by OA-CEUS when it was missed by endoscopy and computed tomography(CT).To our knowledge,this is the first report of GF secondary to CD detected by OA-CEUS up to date.CASE SUMMARY A 29-year-old woman with a 6-year history of CD was admitted to our hospital for abdominal pain and diarrhea for 5 months without obvious predisposing causes.Initial gastroscopy failed to show any evidence of lesions.Colonoscopy revealed multiple erosions,mucosal nodularity,linear ulcers and a cobblestone appearance.A CT scan of her abdomen showed a complex multilocular structure adherent to the greater curvature of the stomach in her left lower abdomen,with fluid,gas and significant surrounding inflammation.CT also demonstrated an abdominal abscess,which was later treated with US-guided drainage.Colonoscopy,gastroscopy and CT missed the presence of a GF.OA-CEUS was performed.A contrast agent made from Chinese yam was taken orally to dilate the lumen of the gastrointestinal tract.A good acoustic window was provided for gastrointestinal tract scanning and the impediment of gas inside the gastrointestinal tract was removed.With the aid of the“window”,a canal with hypoechoic wall was identified connecting the greater curvature of stomach to the splenic colon flexure in free sections.We also observed the hyperechoic gas flowing dynamically inside the canal.Thus,a GF was suspected.US is the first imaging modality taking GF into account.At the same time,OA-CEUS identified the site of the fistula and its two orifices.Gastroscopy was performed again,revealing a small ulcer approximately 5 mm in diameter,which was considered as an orifice.On the basis of OA-CEUS and other examinations,the patient was diagnosed with a GF secondary to CD.Then,laparoscopic exploration,partial stomach resection,transverse colostomy and abdominal abscess drainage were performed.The patient recovered uneventfully.CONCLUSION GFs are rare,occult and potentially life-threatening complications in CD.US is one of the first-line modalities to evaluate CD and its complications.OA-CEUS,a novel technique of US for gut,may be helpful in reducing the possibility of a missed diagnosis of GF. 展开更多
关键词 Gastrocolic FISTULA ULTRASOUND oral agent Crohn’s disease COMPLICATION Case report
下载PDF
Contrast-enhanced ultrasound using SonoVue mixed with oral gastrointestinal contrast agent to evaluate esophageal hiatal hernia: Report of three cases and a literature review 被引量:5
5
作者 Jing-Yu Wang Yan Luo +4 位作者 Wen-Ying Wang Shi-Cheng Zheng Lian He Chun-Yan Xie Li Peng 《World Journal of Clinical Cases》 SCIE 2021年第11期2679-2687,共9页
BACKGROUND Due to a thicker abdominal wall in some patients,ultrasound artifacts from gastrointestinal gas and surrounding tissues can interfere with routine ultrasound examination,precluding its ability to display or... BACKGROUND Due to a thicker abdominal wall in some patients,ultrasound artifacts from gastrointestinal gas and surrounding tissues can interfere with routine ultrasound examination,precluding its ability to display or clearly show the structure of a hernial sac(HS)and thereby diminishing diagnostic performance for esophageal hiatal hernia(EHH).Contrast-enhanced ultrasound(CEUS)imaging using an oral agent mixture allows for clear and intuitive identification of an EHH sac and dynamic observation of esophageal reflux.CASE SUMMARY In this case series,we report three patients with clinically-suspected EHH,including two females and one male with an average age of 67.3±16.4 years.CEUS was administered with an oral agent mixture(microbubble-based SonoVue and gastrointestinal contrast agent)and identified a direct sign of supradiaphragmatic HS(containing the hyperechoic agent)and indirect signs[e.g.,widening of esophageal hiatus,hyperechoic mixture agent continuously or intermittently reflux flowing back and forth from the stomach into the supradiaphragmatic HS,and esophagus-gastric echo ring(i.e.,the“EG”ring)seen above the diaphragm].All three cases received a definitive diagnosis of EHH by esophageal manometry and gastroscopy.Two lesions resolved upon drug treatment and one required surgery.The recurrence rate in follow-up was 0%.The data from these cases suggest that the new non-invasive examination method may greatly improve the diagnosis of EHH.CONCLUSION CEUS with the oral agent mixture can facilitate clear and intuitive identification of HS and dynamic observation of esophageal reflux. 展开更多
关键词 SONOVUE oral gastrointestinal contrast agent Contrast-enhanced ultrasound GASTROINTESTINAL Hiatal hernia Case report
下载PDF
Anti-hyperglycemic effects of aqueous Lenzites betulina extracts from the Philippines on the blood glucose levels of the ICR mice(Mus musculus)
6
作者 Faizal Rajeeb Mangudadatu Hussin Rodel Jonathan Santos Vitor Ⅱ +2 位作者 Julie Ann Oraa Joaquin Melody Mendoza Clerigo Anamy Ma.Caterial Paano 《Asian Pacific Journal of Tropical Biomedicine》 SCIE CAS 2016年第2期155-158,共4页
Objective: To examine the anti-hyperglycemic effects of aqueous Lenzites betulina(L. betulina) extracts on normoglycemic glucose-loaded mice.Methods: Different doses of aqueous extract from L. betulina were administer... Objective: To examine the anti-hyperglycemic effects of aqueous Lenzites betulina(L. betulina) extracts on normoglycemic glucose-loaded mice.Methods: Different doses of aqueous extract from L. betulina were administered to 45 ICR mice(Mus musculus) to determine whether there was an effect of L. betulina extracts on the blood glucose level of the ICR mice. Aqueous extracts of L. betulina were orally gavaged to mice using oral glucose tolerance test. A total of five groups were used to determine the effect of the fungi on blood glucose of the mice. Group A(positive control)was given 16.7 mg/kg glimepiride; Group B(negative control) was given distilled water;Group C(low dosage) was given 200 mg/kg aqueous extract; Group D(mid dosage) was given 400 mg/kg aqueous extract and Group E(high dosage) was given 800 mg/kg aqueous extract. Baseline blood glucose value was firstly acquired before induction of hyperglycemia through D-glucose, after which another check on blood glucose was made after 0.5 h. Immediately, after the acquisition of hyperglycemic blood glucose level, the individual administration of treatments were done. After that, three blood collections were done spanning 3 h with 1 h interval.Results: The low dose(200 mg/kg) and the mid dose(400 mg/kg) of L. betulina extracts were significantly different(P < 0.05) from their respective baseline values throughout the whole experiment with the latter surpassing its baseline value during the 3rd hour. On the other hand, the high dose(800 mg/kg) during the 1st hour after administration was not significantly different(P > 0.05) from its corresponding baseline value, acting faster than the positive control(glimepiride), which only became significantly different(P < 0.05) at the 2nd hour.Conclusions: Aqueous L. betulina extract is able to produce hypoglycemic effects on the mice with all doses, which are able to normalize blood glucose levels at varying times. 展开更多
关键词 anti-hyperglycemic GLUCOSE Lenzites betulina ICR mice oral GLUCOSE tolerance test
下载PDF
Oral Gd-DTPA as a negative gastrointestinal contrast agent in magnetic resonance cholangiopancreatography
7
作者 陈燕萍 张雪林 +1 位作者 昌仁民 成官迅 《Journal of Medical Colleges of PLA(China)》 CAS 2003年第5期325-330,共6页
Objective: To evaluate the value of oral Gd-DTPA as a negative contrast agent during magnetic resonance cholangiopancreatography (MRCP) to eliminate the high signals of the gastrointestinal tract. Methods: To select t... Objective: To evaluate the value of oral Gd-DTPA as a negative contrast agent during magnetic resonance cholangiopancreatography (MRCP) to eliminate the high signals of the gastrointestinal tract. Methods: To select the optimal concentration of oral Gd-DTPA for MRCP, a phantom study was performed followed by clinical trial in 15 cases undergoing MRCP before and after oral Gd-DTPA (in a total volume of 250 ml 1∶5 diluted Gd-DTPA, 1.488 g/L). MRCP images were acquired using two-dimensional single slice fast spin-echo (SSTSE) sequence and half-Fourier acquisition single slice fast spin-echo (HASTE) sequence. Results: The phantom study showed that the 1∶5 diluted oral Gd-DTPA was best in decreasing the signal intensity both in T2-weighted imaging (59.5%) and in HASTE sequence (82.45%). The high signal intensity of the stomach and intestinal fluid was completely suppressed in all the cases. The depictions of the common bile duct and pancreatic duct were markedly improved by using the oral contrast agent (P<0.05). Conclusion: Oral Gd-DTPA is effective and safe for eliminating the high signal of the gastrointestinal tract to improve the depiction of the biliary system by MRCP. 展开更多
关键词 磁共振胰胆管造影术 GD-DTPA
下载PDF
带量采购政策对某医院口服抗肿瘤药临床使用的影响
8
作者 王晓丽 徐慧 +1 位作者 周燕妮 鲍蕾蕾 《解放军药学学报》 CAS 2024年第1期4-7,共4页
目的探讨带量采购政策对某医院口服抗肿瘤药使用的影响,为政策制定和完善提供理论依据。方法选取医院带量采购政策执行前后3年同期(2019、2020、2021年5月20日-12月31日)口服抗肿瘤药的用药数据,对药物的用药频度、限定日费用及实际节... 目的探讨带量采购政策对某医院口服抗肿瘤药使用的影响,为政策制定和完善提供理论依据。方法选取医院带量采购政策执行前后3年同期(2019、2020、2021年5月20日-12月31日)口服抗肿瘤药的用药数据,对药物的用药频度、限定日费用及实际节省费用等进行动态分析。结果政策实施后除甲苯磺酸索拉非尼片未调价外,其他药品价格均出现不同幅度下调,降幅12.00%~76.01%。2020年中选药品除伊马替尼的用药频度较2019年上涨20%外,其他均呈下降趋势,降幅6.35%~86.96%。2021年中选药品的用药频度除替吉奥胶囊和甲苯磺酸索拉非尼片呈下降趋势,降幅分别为57.43%和46.10%,其他均呈上升趋势,涨幅10.71%~500.00%。中选药品2020年的限定日费用降幅1.42%~82.79%,至2021年仍持续下降,降幅61.94%~99.67%;未中选药品限定日费用在2021年也明显下降。带量采购政策实施后口服抗肿瘤药的药费呈逐年下降趋势,2020年实际节省药费总计227.40万元,2021年实际节省药费总计588.17万元。结论带量采购政策的实施对于减轻肿瘤患者的经济负担有显著意义,但要进一步优化中选药品临床应用,完善和监督政策的落实。 展开更多
关键词 药品带量采购 口服抗肿瘤药 用药频度 限定日费用
下载PDF
德谷门冬双胰岛素治疗口服降糖药控制不佳2型糖尿病的效果分析
9
作者 李燕祥 刘永兰 石文霞 《系统医学》 2024年第8期134-136,144,共4页
目的分析德谷门冬双胰岛素(Insulin Degludec/Insulin Aspart,IDegAsp)治疗口服降糖药(Oral Antidiabetic Drugs,OADS)控制不佳2型糖尿病的效果。方法选取2022年8月—2023年7月济南市章丘区中医医院收治的92例OADS控制不佳2型糖尿病患... 目的分析德谷门冬双胰岛素(Insulin Degludec/Insulin Aspart,IDegAsp)治疗口服降糖药(Oral Antidiabetic Drugs,OADS)控制不佳2型糖尿病的效果。方法选取2022年8月—2023年7月济南市章丘区中医医院收治的92例OADS控制不佳2型糖尿病患者为研究对象,参照随机数表法分为两组,各46例。对照组采用甘精胰岛素治疗,研究组采用IDegAsp治疗。比较两组血糖水平、血糖波动值、低血糖发生率。结果治疗3个月后,研究组糖化血红蛋白、餐后2 h血糖、空腹血糖均低于对照组,差异有统计学意义(P均<0.05);研究组血糖标准差、24 h平均血糖值、餐后血糖波动值均低于对照组,差异有统计学意义(P均<0.05)。研究组血糖达标时间(6.15±1.52)d短于对照组的(7.89±1.60)d,差异有统计学意义(t=5.347,P<0.05)。两组低血糖发生率对比,差异无统计学意义(P>0.05)。结论IDegAsp能够有效改善OADS控制不佳2型糖尿病患者的血糖值,抑制其血糖波动,且未增加低血糖发生风险。 展开更多
关键词 德谷门冬双胰岛素 甘精胰岛素 口服降糖药 血糖控制不佳 2型糖尿病
下载PDF
γ⁃Fe2O3@carboxymethyl Cellulose as Potential Oral Nanomedicine for Iron Deficiency Anemia Treatment on Rats 被引量:2
10
作者 Bo Chen Peng Zhao +6 位作者 Qiwei Wang Zhanhang Guo Xin Liu Yan Li Yue Zhang Min Ji Ning Gu 《Journal of Harbin Institute of Technology(New Series)》 EI CAS 2020年第3期158-169,共12页
Oral iron supplements such as ferrous iron salts are major treatment agents for iron deficiency anemia(IDA)due to the convenience of large dose administration and good patient compliance.However,the gastrointestinal a... Oral iron supplements such as ferrous iron salts are major treatment agents for iron deficiency anemia(IDA)due to the convenience of large dose administration and good patient compliance.However,the gastrointestinal adverse impact caused by Fe2+stimulus and low bioavailability severely impedes its therapeutic effects.In recent years,it has been found that nano iron⁃based nanoparticles with high surface⁃to⁃volume ratio and low iron ion leakage can alleviate the toxic effect and improve the gastrointestinal absorbance.For further clinical development,nano materials need to meet the pharmaceutical quality demand.Carboxymethyl cellulose(CMC)is a significant pharmaceutical ingredient applied in approved drug formulations,and polyglucosorbitol carboxymethylether(PSC)has been utilized in iron⁃based nanomedicine ferumoxytol synthesis,both of which can be firmly anchored on iron oxide by carboxyl chelation.In this work,iron oxide nanoparticles(NPs)modified with CMC were designed and synthesized,and the structure composition and physicochemical properties were distinctly characterized.Oral supplement effects on rat IDA were investigated and compared with other recently reported iron supplements including NPs modified with PSC.Results show that the oral nano iron supplement achieved the recovery of hemoglobin and serum iron level in only two weeks with high safety.The nano iron oxide modified with pharmaceutical excipients provides new potential approach for oral iron supplement available in clinics. 展开更多
关键词 iron oxide nanomedicine carboxymethyl cellulose polyglucosorbitol carboxymethylether oral agent iron deficiency anemia
下载PDF
Critical review of topical management of oral hairy leukoplakia 被引量:1
11
作者 Cláudia B Brasileiro Mauro Henrique NG Abreu Ricardo A Mesquita 《World Journal of Clinical Cases》 SCIE 2014年第7期253-256,共4页
Oral hairy leukoplakia(OHL) is a disease associated with Epstein-Barr virus and human immunodeficiency virus infections. OHL is usually an asymptomatic lesion, but in some cases treatment is recommended to reestablish... Oral hairy leukoplakia(OHL) is a disease associated with Epstein-Barr virus and human immunodeficiency virus infections. OHL is usually an asymptomatic lesion, but in some cases treatment is recommended to reestablish the normal characteristics of the tongue, to eliminate pathogenic microorganisms, to improve patient comfort and for cosmetic reasons. Proposed treatments for this condition include surgery, systemic antiviral treatment and topical management. Topical treatment is an inexpensive and safe therapy that is easy to apply, noninvasive, free of systemic adverse effects and effective over a long period of time. The aim of this study was to present a review of the literature for topical therapy for OHL. Gentian violet, retinoids, podophyllin, acyclovir and podophyllin associated with topical antiviral drugs were used to treat OHL. Reports with this focus are limited, and since 2010, no new studies have been published that discuss the efficacy of topical treatments for OHL. Podophyllin with acyclovircream was found to be effective, causing regression of lesions with no recurrences. Additional searches are necessary to provide clinical evidence of topical man agement effectiveness. 展开更多
关键词 oral hairy leukoplakia Human immunodeficiency virus infection Topical treatment Topical agents Recurrence rate
下载PDF
Impact of all oral anti-hepatitis C virus therapy:A metaanalysis 被引量:1
12
作者 Siddharth Bansal Ashwani K Singal +1 位作者 Brendan M Mc Guire Bhupinder S Anand 《World Journal of Hepatology》 CAS 2015年第5期806-813,共8页
AIM:To investigate the efficacy,safety,and cost of treatment of direct acting antivirals(DAAs) with and without peg interferon alfa2a(P),and/or ribavirin(R) in treating hepatitis C virus(HCV) genotype 1 patients.METHO... AIM:To investigate the efficacy,safety,and cost of treatment of direct acting antivirals(DAAs) with and without peg interferon alfa2a(P),and/or ribavirin(R) in treating hepatitis C virus(HCV) genotype 1 patients.METHODS:MEDLINE was searched for randomized controlled trials(RCT) using DAAs for HCV treatment.Phase 1 trials and studies with investigational drugs on genotype 2 or 3,and on human immunodeficiency virus patients were excluded.Data were pooled for sustained virologic response(SVR),serious adverse effects,and drug discontinuation rate on various treatment arms in trials:P + R;1st generation DAA(telaprevir or boceprevir) + P + R;2nd generation DAA(sofosbuvir or simeprevir) + P + R;2nd generation DAA + R;two 2nd generation DAA + R;and two 2nd gen DAA.Data were analyzed separately for each arm for treatment naive and non-responders(NR) to previous treatment.The cost of treatment with each regimen for achieving one SVR was also compared.RESULTS:Twenty three RCTs(n = 9354,62% male,11% cirrhosis) were analyzed.All oral(P free) regimens with combination of 2 DAA achieved SVR above 95%.The cost of treatment to achieve an SVR with DAA based regimens was lower for NR compared to P+R regimen.However,the cost per SVR remained higher for treatment naive patients.CONCLUSION:Second generation and emerging DAAs are promising agents in HCV treatment,with a very high level of safety and efficacy.An important drawback is their high cost.However,the present meta-analysis shows that the cost per SVR for non responders(but not for naive patients) was lower compared to P + R.This finding together with the superior safety profile and better compliance makes these drugs highly attractive.It is possible that further reduction in treatment duration may make them even more cost effective. 展开更多
关键词 丙肝 元分析 指导代理 antivirals 口头的代理人 更新的代理人 丙肝病毒
下载PDF
Development of Film Dosage Forms Containing Miconazole for the Treatment of Oral Candidiasis
13
作者 Yoshifumi Murata Takashi Isobe +2 位作者 Kyoko Kofuji Norihisa Nishida Ryosei Kamaguchi 《Pharmacology & Pharmacy》 2013年第3期325-330,共6页
Film dosage forms (FDs) containing miconazole (MCZ) for the treatment of oral candidiasis were prepared using water-soluble polysaccharides, and the dissolution profiles of MCZ from the FDs were investigated. In addit... Film dosage forms (FDs) containing miconazole (MCZ) for the treatment of oral candidiasis were prepared using water-soluble polysaccharides, and the dissolution profiles of MCZ from the FDs were investigated. In addition, the forms were modified by the addition of a surface active agent to accelerate the drug dissolution rate. Circular films incorporating MCZ were obtained using each polysaccharide. Most FDs were easy to handle and resistant to tearing. No diffraction peaks were observed in the X-ray diffractograms of FDs. FDs prepared with sodium alginate or pullulan immediately swelled and disintegrated in aqueous medium, whereas MCZ incorporated in the FD gradually dissolved. A marked acceleration in the MCZ dissolution rate was observed when FD was prepared with polysaccharide containing a surfactant. These results confirmed that modified FDs are useful for treating localized conditions in the oral cavity, such as oral candidiasis, and that FDs can simplify the administration of drugs to patients. 展开更多
关键词 FILM DOSAGE Form MICONAZOLE oral CANDIDIASIS Natural POLYSACCHARIDE Surface Active agent
下载PDF
早期胰岛素强化与口服降糖药治疗老年2型糖尿病的临床疗效分析 被引量:1
14
作者 臧道军 龚红燕 《糖尿病新世界》 2023年第3期76-79,共4页
目的观察早期胰岛素强化与口服降糖药治疗老年2型糖尿病临床疗效。方法选取2021年1月—2022年1月常州市德安医院收治的82例老年2型糖尿病患者,以随机数表法分组,基础组采用口服降糖药治疗(41例),强化组采取早期胰岛素强化治疗(41例),比... 目的观察早期胰岛素强化与口服降糖药治疗老年2型糖尿病临床疗效。方法选取2021年1月—2022年1月常州市德安医院收治的82例老年2型糖尿病患者,以随机数表法分组,基础组采用口服降糖药治疗(41例),强化组采取早期胰岛素强化治疗(41例),比较两组血糖指标改善情况、疗效、胰岛素指标。结果强化组患者用药后空腹血糖(FBG)、餐后2 h血糖(2 hPG)及糖化血红蛋白(HbA1c)低于基础组,治疗总有效率显著高于基础组,用药后30 min的C肽/血糖(ΔCP30/ΔG30)、120 min的C肽/血糖(ΔCP120/ΔG120)显著高于基础组,胰岛素抵抗指数(HOMA-IR)及餐后2 h胰岛素(2 hFINS)含量低于基础组,差异有统计学意义(P<0.05)。结论与口服降糖药相比,早期胰岛素强化疗法用于临床老年2型糖尿病治疗中具有更为显著的疗效,胰岛素指标改善效果更佳。 展开更多
关键词 早期胰岛素强化 口服降糖药 老年患者 2型糖尿病 胰岛素抵抗
下载PDF
国家集采的口服降糖药对糖尿病患者的用药影响分析
15
作者 洪丽萍 杨丽雄 《海峡药学》 2023年第12期68-71,共4页
目的统计某院门诊口服降糖药的使用情况和药品的日均费用,分析降糖药进入国家集采后对糖尿病患者的用药影响。方法采用世界卫生组织推荐的限定日剂量分析方法,对某院门诊常用的口服降糖药使用情况和日均费用进行统计分析。结果盐酸二甲... 目的统计某院门诊口服降糖药的使用情况和药品的日均费用,分析降糖药进入国家集采后对糖尿病患者的用药影响。方法采用世界卫生组织推荐的限定日剂量分析方法,对某院门诊常用的口服降糖药使用情况和日均费用进行统计分析。结果盐酸二甲双胍片、阿卡波糖片、恩格列净片的用药频度(DDDs)分别排在前三位(三者均为国家集采药品),而日均费用(DDC)分别排在第11、16和8位。对同类降血糖药进行比较,集采药品的使用量绝大多数均大于非集采药品,而日均费用均低于非集采药品。结论国家药品集中带量采购的实施,对糖尿病患者的用药产生了很大的影响。在某院,双胍类、α糖苷酶抑制剂仍是某院临床一线治疗药物,而SGLT⁃Ⅱ抑制剂作为新型口服降糖药,对糖尿病患者的肾脏和心血管均有保护作用,弥补了传统降血糖药的不足,满足了更多2型糖尿病患者的用药需求,所以在临床上的使用越来越广泛。 展开更多
关键词 口服降糖药 用药频度 日均费用 集采药品
下载PDF
基于口服抗肿瘤药物患者健康教育工具护理干预对肺癌患者化疗症状群改善效果的评价
16
作者 张月葵 曹燕 +2 位作者 陈小盼 蔡燕婵 彭汉健 《当代医学》 2023年第21期174-176,共3页
目的分析基于口服抗肿瘤药物患者健康教育工具(MOATT)护理干预对肺癌患者化疗症状群的改善效果。方法选取2019年1月至2020年1月本院收治的120例需服用靶向药物治疗肺癌患者作为研究对象,按照随机抽签法分为参照组与研究组,每组60例。参... 目的分析基于口服抗肿瘤药物患者健康教育工具(MOATT)护理干预对肺癌患者化疗症状群的改善效果。方法选取2019年1月至2020年1月本院收治的120例需服用靶向药物治疗肺癌患者作为研究对象,按照随机抽签法分为参照组与研究组,每组60例。参照组采用常规护理干预,研究组采用基于MOATT护理干预,比较两组干预前后化疗症状对生活干扰程度评分及干预满意度。结果干预前,两组一般活动、情绪、工作、人际关系、走路、生活乐趣评分比较差异无统计学意义;干预后,两组一般活动、情绪、工作、人际关系、走路、生活乐趣评分均低于干预前,且研究组低于参照组,差异有统计学意义(P<0.05)。研究组干预总满意度为93.33%,高于参照组的78.33%,差异有统计学意义(P<0.05)。结论基于MOATT护理干预应用于肺癌患者,不仅可显著降低患者化疗症状群严重程度,还可有效改善化疗症状对其生活的干扰程度,有利于提高护理干预满意度,值得临床推广应用。 展开更多
关键词 肺癌 口服抗肿瘤药物患者健康教育工具 护理干预 化疗症状群 生活干扰 满意度
下载PDF
基础胰岛素联合口服降糖药治疗效果不佳的2型糖尿病患者的治疗策略选择:伞形评价 被引量:2
17
作者 牛亚平 柴三葆 +4 位作者 马璟籽 章萌 刘佐相 武珊珊 孙凤 《药物流行病学杂志》 CAS 2023年第11期1275-1284,共10页
目的对基础胰岛素联合一线口服降糖药(二甲双胍/磺脲类药物)治疗效果不佳的2型糖尿病(T2DM)患者的不同治疗策略进行伞形评价,为患者推荐最佳治疗策略提供科学依据。方法计算机检索PubMed、Embase、Cochrane Library、SinoMed、CNKI、Wan... 目的对基础胰岛素联合一线口服降糖药(二甲双胍/磺脲类药物)治疗效果不佳的2型糖尿病(T2DM)患者的不同治疗策略进行伞形评价,为患者推荐最佳治疗策略提供科学依据。方法计算机检索PubMed、Embase、Cochrane Library、SinoMed、CNKI、WanFang Data和VIP数据库,搜集基础胰岛素联合一线口服降糖药治疗T2DM效果不佳的系统评价(SR)/Meta分析(MA),其原始研究为随机对照试验(RCT),检索时限均从建库至2023年9月13日,由2名研究者独立进行文献筛选、数据提取和文献质量评估,采用R 4.2.2软件中的metaumbrella包进行伞形评价。结果共纳入1篇SR和8篇MA,包括72个RCT,24095例患者,涉及的后续治疗措施有胰高糖素样肽1受体激动剂(GLP-1RA)、二肽基肽酶Ⅳ抑制剂(DPP-4i)、钠葡萄糖共转运蛋白2抑制剂(SGLT-2i)、噻唑烷二酮类药(TZD)等。结果显示,与安慰剂相比,GLP-1RA[WMD=-3.67,95%CI(-5.81,-1.53),P=0.001]、DPP-4i[WMD=-5.56,95%CI(-7.40,-3.73),P<0.001]和SGLT-2i[WMD=-5.34,95%CI(-9.56,-1.13),P=0.013]均可显著降低糖化血红蛋白(%)水平;阳性药物比较中,GLP-1RA vs.甘精胰岛素利司那肽固定比例复方制剂(IGlarLixi)[WMD=7.49,95%CI(7.01,7.92),P<0.001],GLP-1RA vs.德谷胰岛素利拉鲁肽注射液(IDegLira)[WMD=0.83,95%CI(0.11,1.54),P=0.023],显示GLP-1RA的降血糖效果不及IGlarLixi和IDegLira。与安慰剂相比,GLP-1RA可显著减轻体重(kg)[WMD=-3.46,95%CI(-5.30,-1.63),P<0.001];阳性药物比较中,GLP-1RA vs.IGlarLixi[WMD=-8.40,95%CI(-8.86,-7.93),P<0.001],GLP-1RA vs.IDegLira[WMD=-0.53,95%CI(-0.99,-0.07),P=0.025],显示GLP-1RA的降体重效果优于IGlarLixi和IDegLira。与安慰剂相比,TZD[OR=1.51,95%CI(1.11,2.05),P=0.009]和GLP-1RA[OR=1.24,95%CI(1.03,1.49),P=0.023]均会增加低血糖发生风险;阳性药物比较中,GLP-1RA vs.IDegLira[OR=1.22,95%CI(1.04,1.43),P=0.014],显示GLP-1RA导致的低血糖发生风险高于IDegLira。结论后续治疗使用GLP-1RA、DPP-4i、SGLT-2i能更好地控制血糖,且GLP-1RA有降低体重优势,但使用GLP-1RA的患者低血糖风险较高。 展开更多
关键词 基础胰岛素 口服降糖药 2型糖尿病 治疗效果不佳 伞形评价
下载PDF
中成药联合口服降糖西药治疗2型糖尿病效果的网状Meta分析 被引量:1
18
作者 陈宇阳 赵恒侠 +4 位作者 张靖悦 连李荣 李惠林 刘德亮 楚淑芳 《世界中医药》 CAS 2023年第18期2607-2619,2625,共14页
目的:评估临床常用的中成药分别联合常用口服降糖西药治疗2型糖尿病的有效性。方法:检索国家知识基础设施数据库(CNKI)、中国学术期刊数据库(CSPD)、中文科技期刊数据库(CCD)、中国生物医学文献数据库(CBM)、PubMed、Embase、Cochrane L... 目的:评估临床常用的中成药分别联合常用口服降糖西药治疗2型糖尿病的有效性。方法:检索国家知识基础设施数据库(CNKI)、中国学术期刊数据库(CSPD)、中文科技期刊数据库(CCD)、中国生物医学文献数据库(CBM)、PubMed、Embase、Cochrane Library等数据库,文献时间范围为建库至2020年12月23日,根据纳入、排除标准进行文献筛选、资料提取并评价纳入研究的偏倚风险后,分别对不同结局指标包括空腹血糖、餐后2 h血糖、糖化血红蛋白采用网状Meta分析进行有效性比较及排序。结果:1)空腹血糖方面:7种中成药联合口服降糖西药均优于单纯口服降糖西药治疗,参芪降糖颗粒联用口服降糖西药疗效更为显著。2)餐后血糖方面:除消渴丸外,其余6种中成药联合口服降糖西药治疗效果均优于单纯口服降糖西药治疗,参芪降糖颗粒联用口服降糖西药疗效最为显著;3)糖化血红蛋白方面:除参芪降糖颗粒外,其余6种中成药联合口服降糖西药治疗效果均优于单纯口服降糖西药治疗,其中消渴丸疗效最佳。结论:7种中成药均能改善空腹血糖、餐后血糖、糖化血红蛋白,但由于临床试验的局限性,仍需要更多严谨、科学的临床试验为临床治疗提供切实有效的依据。 展开更多
关键词 网状Meta分析 系统评价 随机对照试验 疗效 中成药 口服降糖西药 2型糖尿病
下载PDF
白头翁口服液的提取与澄清工艺的优化
19
作者 韩汝硕 郑美如 +5 位作者 张趁 戎畅 要纬玉 史万玉 杜西翠 王晓丹 《饲料研究》 CAS 北大核心 2023年第23期90-95,共6页
试验旨在优化白头翁口服液的提取和澄清工艺。采用L9(34)正交试验对白头翁口服液的水提与澄清工艺进行优化。试验固定提取次数3次,以液料比、浸泡时间、提取时间为考察因素,以盐酸小檗碱含量为评价指标,对水提工艺进行探索研究;以药液... 试验旨在优化白头翁口服液的提取和澄清工艺。采用L9(34)正交试验对白头翁口服液的水提与澄清工艺进行优化。试验固定提取次数3次,以液料比、浸泡时间、提取时间为考察因素,以盐酸小檗碱含量为评价指标,对水提工艺进行探索研究;以药液浓度、澄清剂用量、絮凝温度为考察因素,以吸光度、盐酸小檗碱保留率为综合评价指标,对澄清工艺进行探索研究,同时对絮凝澄清工艺与醇沉澄清工艺进行比较。结果显示,白头翁口服液的最佳水提工艺为液料比10 mL/g、浸泡时间30 min、提取次数3次、每次提取时间70 min。最佳澄清工艺为药液浓度1∶7 g/mL,ZTC1+1天然澄清剂用量6%A、3%B,絮凝温度60℃。絮凝澄清工艺除杂后盐酸小檗碱平均保留率为70.89%,而醇沉澄清工艺的盐酸小檗碱平均保留率仅56.72%,且不同批次絮凝澄清制备口服液测定的含量保留率相对标准偏差(RSD)值<1.00%(n=3)。研究表明,试验优化的提取澄清工艺稳定可靠,可用于工业化生产。 展开更多
关键词 白头翁口服液 提取工艺 澄清工艺 ZTC1+1天然澄清剂 盐酸小檗碱
下载PDF
2020—2022年某院住院患者口服降糖药物使用情况分析
20
作者 卢燕辉 陈少壮 +3 位作者 范彩云 翁丽玲 叶岩荣 沈赟 《中国药物评价》 2023年第5期445-448,共4页
目的:统计分析某院住院患者口服降糖药的使用情况,为口服降糖药的合理使用提供参考。方法:统计2020—2022年某院住院患者口服降糖药的应用数据,获取该类药年销售总金额和年出库总量等相关信息,采用世界卫生组织推荐的限定日剂量(DDD)分... 目的:统计分析某院住院患者口服降糖药的使用情况,为口服降糖药的合理使用提供参考。方法:统计2020—2022年某院住院患者口服降糖药的应用数据,获取该类药年销售总金额和年出库总量等相关信息,采用世界卫生组织推荐的限定日剂量(DDD)分析法,回顾性分析住院口服降糖药的销售金额、用药频度(DDDs)、限定日费用(DDC)及排序比(B/A)等指标。结果:某院2020—2022年各类口服降糖药的销售总金额呈每年递增趋势,其中二肽基肽酶(DPP-4)抑制剂的销售金额连续3年位列首位;2021—2022年二甲双胍和达格列净的DDD位列前2位;吡格列酮DDC连续3年列首位,其中二甲双胍DDC下降最为明显;二甲双胍B/A最大,利格列汀B/A最小。结论:2020—2022年某院住院口服降糖药的临床选用基本合理,符合指南推荐。 展开更多
关键词 口服降糖药 销售金额 用药频度 限定日费用 排序比
下载PDF
上一页 1 2 20 下一页 到第
使用帮助 返回顶部